Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI3726 in mCRPC
NCT02991911Phase 1Completed
- Sponsor
- MedImmune
- Start
- Jan 2017
- Primary completion
- Sep 2019
- Modality
- Antibody Fragments, Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 1, open-label trial of MEDI3726 in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by MedImmune. Primary endpoints: Occurrence of adverse events (AEs), Occurrence of serious adverse events (SAEs) and 4 more. Started Jan 2017; status: completed.
02
Drugs
MEDI3726
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02991911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991911.